Viromed Medical AG has provided a strategic update on its operational orientation, maintaining its focus on sustainable, technology-driven growth in the international MedTech market. The company concentrates on developing innovative medical devices and conducting translational research in severe respiratory diseases, particularly ventilator-associated pneumonia.
Over the past two years, Viromed has developed two novel cold plasma medical devices: ViroCAP® for medical wound healing and PulmoPlas®, a globally unique cold plasma system for applications in pneumology and respiratory tract infections. The company attributes particular importance to PulmoPlas® as a next-generation technological platform that forms the basis for future scaling potential across multiple medical indication areas.
In the research domain, Viromed has established a high-performance scientific consortium consisting of Hannover Medical School, the Helmholtz Centre for Infection Research in Braunschweig, and the Leibniz Institute in Jena. This network brings together international top-level expertise in infectiology, pneumology, and translational research, enabling the development of novel therapeutic approaches for diseases of the upper and lower respiratory tract. The comprehensive publication of results by MHH and HZI is expected at the end of January 2026.
For further technological development, Viromed works closely with Relyon Plasma, a subsidiary of TDK. International partnerships in Europe, Korea, and Turkey have been established, supporting future market entry and underscoring the global relevance of the technology. As a result of the strategic focus on research, development, and establishing international market structures, longer innovation cycles naturally arise, leading the company to refrain from communicating short-term operational interim updates.
Viromed's corporate strategy is geared toward long-term value generation, with research and development programs consistently aligned with medical benefit, clinical relevance, and sustainable market potential. The company is recognized as a pioneer in pneumological research and plasma technology, with its scientific network's innovation work having the potential to significantly shape future therapeutic approaches for severe respiratory infections. According to its assessment, Viromed will play a significant role in the global fight against pathogenic germs in coming years, particularly with PulmoPlas®.
Additionally, Viromed has successfully overcome stringent regulatory hurdles for ViroCAP® approval over the past 18 months, with market acceptance and demand already very high. The company maintains its website at https://www.viromed-medical-ag.de for corporate information.
